With 4.62 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.73 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $0.335 whereas the lowest price it dropped to was $0.2415. The 52-week range on CPHI shows that it touched its highest point at $0.60 and its lowest point at $0.13 during that stretch. Beta for the stock currently stands at 0.70.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CPHI was up-trending over the past week, with a rise of 31.26%, but this was up by 34.25% over a month. Three-month performance dropped to -3.67% while six-month performance rose 0.78%. The stock lost -48.59% in the past year, while it has gained 11.78% so far this year.
Float and Shares Shorts:
At present, 17.86 million CPHI shares are outstanding with a float of 9.38 million shares on hand for trading. On 2024-02-15, short shares totaled 93597.0, which was 88.0 higher than short shares on 1705017600. In addition to Ms. Zhilin Li as the firm’s President, CEO, Chairman & Interim CFO, Ms. Huang Na C.F.A. serves as its BOD Secretary & IR Manager.
Institutional Ownership:
Through their ownership of 0.00211 of CPHI’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, CPHI reported revenue of $1100152.0 and operating income of -$1085257.0. The EBITDA in the recently reported quarter was -$386854.0 and diluted EPS was -$0.06.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
